INTS Intensity Therapeutics
- 3.925
- 0.0000.00%
Intensity Therapeutics News
Express News | Intensity Therapeutics-Got Nasdaq Letter Due to Resignation of Daniel Donovan From Audit Committee, Co Not Compliant With Nasdaq Listing Rule 5605
Press Release: Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) Shares
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares Company generated approximately $2.8M of non-dilutive funding to extend cash runway WESTPORT, Conn., March 26, 2024 (GL
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Intensity Therapeutics Price Target Maintained With a $12.00/Share by Benchmark
Benchmark Reiterates Speculative Buy on Intensity Therapeutics, Maintains $12 Price Target
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
Intensity Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/21/2024 130.77% Benchmark → $12 Reiterates Speculative Buy → Speculative Buy 11/14/2023 130.77% Benchma
Express News | Intensity Therapeutics Shares Are Are Trading Higher After the Company Reported a Year-over-year Increase in FY24 EPS Results
Intensity Therapeutics Reports FY23 EPS $(1.38) Vs $(2.22) YoY
Year-End 2023 Financial ResultsResearch and development expenses were $4.8 million for the year ended December 31, 2023, compared to $5.1 million for the same period in 2022. The decrease was primaril
Express News | Intensity Therapeutics 2023 Year-End Cash And Investments $14.8M
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces full year 2023 financial results and provides a review of 2023 accomplishments and anticipated upcoming developments.
12 Health Care Stocks Moving In Monday's Intraday Session
GainersRegencell Bioscience (NASDAQ:RGC) shares rose 130.9% to $10.39 during Monday's regular session. The company's market cap stands at $135.2 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares in
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersNKGen Biotech (NASDAQ:NKGN) shares increased by 69.4% to $1.46 during Wednesday's pre-market session. The market value of their outstanding shares is at $31.9 million. Creative Medical Tech (NA
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Intensity Therapeutics is a late-stage clinical biotechnology company that applies novel engineered chemistry to turn "cold" tumors "hot" by enabling its aqueous cytotoxic-containing drug product, INT230-6, to mix and saturate the dense, high-fat pressurized environment of the tumor.
Intensity Therapeutics Unveils New Incentive Compensation Plan
Intensity Therapeutics To Initiate Phase 3 Sarcoma Trial In H1 - Quick Facts
Intensity Therapeutics Gets FDA Green Light for Phase 3 Study
By Colin Kellaher Intensity Therapeutics has received U.S. Food and Drug Administration approval to launch a Phase 3 study of its lead drug candidate INT230-6 in soft tissue sarcoma. The Shelton, Co
Intensity Therapeutics Announced A Business Update Reflecting Progress In Its Phase 3 Sarcoma Clinical Program; FDA Provided "Study May Proceed Letter" For Phase 3 Within 30 Day Period Following IND Submission
IND Submission for Phase 3In the fourth quarter of 2023, the Company submitted a new Investigational New Drug ("IND") to the Food and Drug Administration ("FDA"). The submission included the phase 3 p
12 Health Care Stocks Moving In Thursday's Pre-Market Session
GainersCingulate (NASDAQ:CING) stock moved upwards by 188.5% to $11.51 during Thursday's pre-market session. The market value of their outstanding shares is at $10.7 million. SenesTech (NASDAQ:SNES) s
12 Health Care Stocks Moving In Friday's After-Market Session
GainersAlaunos Therapeutics (NASDAQ:TCRT) stock rose 20.9% to $0.06 during Friday's after-market session. The company's market cap stands at $13.2 million. Impel Pharmaceuticals (NASDAQ:IMPL) shares r
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersTriSalus Life Sciences (NASDAQ:TLSI) stock moved upwards by 38.3% to $8.23 during Thursday's regular session. The market value of their outstanding shares is at $216.5 million. Immix Biopharma
CAN, TPIC and MOTS Among Mid-day Movers
Analysis
Price Target
No Data
